Interestingly, Bergamaschi et al. demonstrated an increase of EPO, after Infliximab treatment in IBD patients [24]; thus, we anticipated anti-TNF blockade to restore EPO production and induce ERFE, further reducing hepcidin levels. The gene discussed is TNF; the disease is inflammatory bowel disease.